查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2130841

對下一代診斷測試市場到 2035 年的分析和預測：按類型、產品、服務、技術、組件、應用、最終用戶、解決方案、模式和階段分類。

Next-Gen Diagnostic Tests Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Solutions, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球新一代診斷檢測市場預計將從2025年的45億美元成長到2035年的98億美元，複合年成長率（CAGR）為7.9%。這一成長主要得益於個人化醫療的進步、對疾病早期檢測需求的不斷成長、診斷工具的技術創新以及全球醫療保健支出的增加。下一代診斷檢測市場呈現中等程度的整合結構，其主要細分市場包括分子診斷（約佔45%的市場佔有率）、免疫檢測（30%）和即時檢測（25%）。這些細分市場的成長主要由傳染病檢查、腫瘤學和基因檢測等領域的應用所驅動。精準醫療和個人化醫療的進步正推動市場檢測數量的穩定成長，這一趨勢在分子診斷領域尤為顯著。

競爭格局由全球性和區域性公司並存，其中羅氏診斷和雅培等全球性企業在創新和市場佔有率方面發揮主導作用。先進創新在快速、精準的診斷解決方案的開發方面尤其顯著。為拓展技術能力和地理企業發展，企業併購和策略聯盟頻繁發生。近期趨勢表明，企業正致力於整合人工智慧和機器學習技術以提高診斷的準確性和效率，這進一步加劇了市場參與企業之間的競爭。

市場區隔
類型 分子診斷、免疫檢測、即時檢測、伴隨診斷、液態生物檢體、微生物組檢測、基因檢測、蛋白質體學、代謝體學等。
產品 設備、試劑/試劑盒、軟體、耗材及其他
服務 諮詢服務、維護服務、訓練服務、資料管理服務等。
科技 次世代定序、聚合酵素鏈鎖反應、質譜分析、微陣列、流式細胞技術、CRISPR 等技術。
成分 硬體、軟體、服務及其他
目的 腫瘤科、感染疾病、循環系統、神經科、產前檢查、罕見疾病科等。
最終用戶 醫院、診斷檢測實驗室、學術和研究機構、製藥和生物技術公司等。
解決方案 整合解決方案、獨立解決方案、客製化解決方案等等。
模式 全自動、半自動、手動、其他
步 研究、開發、商業化及其他

在下一代診斷檢測市場中，「類型」細分至關重要，分子診斷憑藉其準確性和檢測基因標記的能力佔據主導地位。感染疾病和癌症的日益普及推動了這個細分市場的發展，因為早期檢測對於這些疾病至關重要。即時檢測（POC​​T）也正蓬勃發展，這得益於市場對快速、現場診斷解決方案的需求。個人化醫療的興起進一步促進了這個細分市場的成長。

在「技術」領域，聚合酵素鏈鎖反應（PCR）技術憑藉其在核酸檢測方面的高靈敏度和特異性，仍然佔據主導地位並持續保持核心地位。次世代定序（NGS）技術正迅速發展，其全面的基因組分析能力對於精準醫療至關重要。人工智慧（AI）和機器學習的融合正在提高診斷的準確性和效率，這是技術進步的關鍵趨勢。

在「應用」領域，腫瘤診斷處於領先地位，這主要得益於癌症發生率的上升以及對早期精準檢測的需求。感染疾病診斷也佔據了相當大的佔有率，尤其是在新冠肺炎等全球健康危機之後。產前檢測和基因檢測的需求也在不斷成長，這反映出人們對生殖健康技術的認知不斷提高以及這些技術的進步。

在「終端使用者」領域，醫院和診斷實驗室作為提供全面醫療保健服務的重要機構，是主要的需求來源。居家醫療和遠端醫療的興起，因其便利性和可及性，正在擴大家用診斷試劑盒的市場。實驗室也是重要的市場貢獻者，它們不斷探索創新的診斷解決方案和技術。

在「組件」領域，試劑和試劑盒在診斷測試中發揮至關重要的作用，佔據主導地位。隨著先進試劑能夠提高測試的準確性和可靠性，市場對這類試劑的需求也不斷成長。儀器和軟體同樣重要，持續的創新旨在實現自動化並提升數據分析能力。雲端解決方案的整合是一個顯著的趨勢，它有助於在整個醫療保健網路中實現即時資料共用和協作。

區域概覽

北美：北美的下一代診斷檢測市場已趨於成熟，這得益於先進的醫療基礎設施和大量的研發投入。美國在該地區處於領先地位，生物技術和製藥行業的需求強勁。加拿大也為該市場做出了重要貢獻，其重點是個人化醫療和疾病早期檢測。

歐洲：歐洲市場已趨於成熟，醫療保健和生命科學領域的需求強勁。德國、英國和法國等主要國家在政府主導的措施支持下，大力推動診斷技術的創新，尤其注重精準醫療和早期療育。

亞太地區：亞太地區正經歷快速成長，這主要得益於醫療保健支出不斷成長和技術進步。中國和印度透過擴大醫療基礎設施以及日益重視早期診斷和預防醫學，做出了重大貢獻。日本也憑藉其技術優勢發揮重要作用。

拉丁美洲：拉丁美洲市場是一個新興市場，其中巴西和墨西哥是診斷檢測需求的主要驅動力。該地區的成長得益於醫療保健服務的改善和對先進診斷解決方案日益成長的認知，但在基礎設施和法律規範方面仍面臨挑戰。

中東和非洲：中東和非洲地區尚處於市場發展的初期階段。阿拉伯聯合大公國（阿拉伯聯合大公國）和南非是值得關注的國家，它們不斷增加對醫療基礎設施的投資，並專注於疾病的早期檢測。然而，該地區也面臨經濟不平等和先進技術普及程度有限的挑戰。

主要趨勢和促進因素

趨勢一：基因測序技術的進步

下一代診斷檢測市場正受到基因測序技術快速發展的顯著影響。這些進步使得診斷解決方案更加精準、快速且經濟高效，從而實現早期檢測和個人化治療方案的發展。將人工智慧和機器學習技術融入基因組數據分析，進一步提高了診斷準確性，使其成為精準醫療的關鍵要素。這一趨勢正促使更多醫療機構採用這些技術，以期改善病患的治療效果。

趨勢二：監理支援與框架

全球衛生監管機構的支持性法規結構是推動下一代診斷檢測市場發展的主要動力。監管機構日益認知到創新診斷解決方案在改善醫療服務方面的重要性。簡化的核准流程和清晰的指導方針鼓勵企業加強研發投入，從而更快地將新的診斷技術推向市場。這種監管支援對於促進創新和確保可靠診斷檢測的可用性至關重要。

趨勢三：即時檢測的興起

在對快速準確診斷結果的需求驅動下，即時檢測（POC​​）的需求日益成長。新一代診斷測試擴大被設計用於臨床環境，為患者管理帶來便利和效率。這一趨勢在偏遠地區和醫療資源匱乏的地區尤其顯著，這些地區傳統實驗室設施有限。在臨床環境中進行檢測的能力正在改變醫療服務模式，它能夠幫助醫護人員及時做出決策，並減輕中心檢查室的負擔。

趨勢四：數位健康科技的整合

數位健康技術與新一代診斷檢測技術的融合正在革新市場。穿戴式裝置、行動醫療應用和遠端醫療平台正被用於即時採集和分析健康數據。這種融合實現了持續監測和個人化醫療解決方案，從而提升了患者的參與度和治療依從性。數位健康與診斷技術的融合正在創造新的創新機遇，並提高整個醫療系統的效率。

趨勢五：對感染疾病診斷日益關注的關注

近期全球衛生危機凸顯了強大的感染疾病診斷能力的重要性。人們越來越關注開發能夠快速識別病原體並提供可操作資訊以輔助疾病管理的下一代診斷測試。這一趨勢正在推動研發投入，以開發出不僅快速且準確，而且擴充性能夠應對新出現的感染疾病威脅的測試方法。作為加強全球醫療衛生韌性和應對能力努力的一部分，對感染疾病診斷的關注預計將持續下去。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 分子診斷
    • 免疫測量
    • 即時檢測
    • 伴隨診斷
    • 液態生物檢體
    • 微生物組檢測
    • 基因檢測
    • 蛋白質體學
    • 代謝體學
    • 其他
  • 市場規模及預測：依產品分類
    • 裝置
    • 試劑和試劑盒
    • 軟體
    • 消耗品
    • 其他
  • 市場規模及預測：依服務分類
    • 諮詢服務
    • 維護服務
    • 培訓服務
    • 資料管理服務
    • 其他
  • 市場規模及預測：依技術分類
    • 次世代定序
    • 聚合酵素鏈鎖反應
    • 質譜分析
    • 微陣列
    • 流式細胞技術
    • CRISPR
    • 其他
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 感染疾病
    • 循環系統
    • 神經病學
    • 產前檢查
    • 罕見疾病
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷檢查室
    • 學術和研究機構
    • 製藥和生物技術公司
    • 其他
  • 市場規模及預測：依組件分類
    • 硬體
    • 軟體
    • 服務
    • 其他
  • 市場規模及預測：按模式
    • 自動化
    • 半自動
    • 手動的
    • 其他
  • 市場規模及預測：依階段分類
    • 研究
    • 發展
    • 商業化
    • 其他
  • 市場規模及預測：按解決方案分類
    • 整合解決方案
    • 獨立解決方案
    • 客製化解決方案
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Siemens Healthineers
  • Danaher Corporation
  • Becton Dickinson and Company
  • Bio-Rad Laboratories
  • Hologic
  • Qiagen
  • Illumina
  • Agilent Technologies
  • PerkinElmer
  • bioMerieux
  • Sysmex Corporation
  • Genomic Health
  • Luminex Corporation
  • Myriad Genetics
  • Exact Sciences
  • Cepheid
  • Adaptive Biotechnologies

第9章 關於我們

簡介目錄
Product Code: GIS32903

The global Next-Gen Diagnostic Tests Market is projected to grow from $4.5 billion in 2025 to $9.8 billion by 2035, at a compound annual growth rate (CAGR) of 7.9%. Growth is driven by advancements in personalized medicine, increased demand for early disease detection, and technological innovations in diagnostic tools, coupled with rising healthcare expenditure globally. The Next-Gen Diagnostic Tests Market is characterized by a moderately consolidated structure, with key segments including molecular diagnostics (approximately 45% market share), immunoassays (30%), and point-of-care testing (25%). These segments are driven by applications in infectious disease testing, oncology, and genetic testing. The market is witnessing a steady increase in the volume of tests conducted, particularly in molecular diagnostics, due to advancements in precision medicine and personalized healthcare.

The competitive landscape features a mix of global and regional players, with global companies such as Roche Diagnostics and Abbott Laboratories leading in innovation and market presence. There is a high degree of innovation, particularly in the development of rapid and accurate testing solutions. Mergers and acquisitions, along with strategic partnerships, are prevalent as companies aim to expand their technological capabilities and geographic reach. Recent trends indicate a focus on integrating AI and machine learning to enhance diagnostic accuracy and efficiency, further intensifying competition among market participants.

Market Segmentation
TypeMolecular Diagnostics, Immunoassays, Point-of-Care Testing, Companion Diagnostics, Liquid Biopsy, Microbiome Testing, Genetic Testing, Proteomics, Metabolomics, Others
ProductInstruments, Reagents & Kits, Software, Consumables, Others
ServicesConsulting Services, Maintenance Services, Training Services, Data Management Services, Others
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, Microarray, Flow Cytometry, CRISPR, Others
ComponentHardware, Software, Services, Others
ApplicationOncology, Infectious Diseases, Cardiology, Neurology, Prenatal Testing, Rare Diseases, Others
End UserHospitals, Diagnostic Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Others
SolutionsIntegrated Solutions, Standalone Solutions, Custom Solutions, Others
ModeAutomated, Semi-Automated, Manual, Others
StageResearch, Development, Commercialization, Others

In the Next-Gen Diagnostic Tests Market, the 'Type' segment is pivotal, with molecular diagnostics leading due to their precision and ability to detect genetic markers. This segment is driven by the increasing prevalence of infectious diseases and cancer, where early detection is critical. Point-of-care testing is also gaining traction, supported by the demand for rapid and on-site diagnostic solutions. The shift towards personalized medicine is further propelling growth in this segment.

The 'Technology' segment is dominated by polymerase chain reaction (PCR) technology, which remains a cornerstone due to its high sensitivity and specificity in detecting nucleic acids. Next-generation sequencing (NGS) is rapidly advancing, driven by its comprehensive genomic analysis capabilities, which are essential for precision medicine. The integration of artificial intelligence and machine learning is enhancing diagnostic accuracy and efficiency, marking a significant trend in technological advancements.

Within the 'Application' segment, oncology diagnostics are at the forefront, fueled by the rising incidence of cancer and the need for early and accurate detection. Infectious disease diagnostics also hold a substantial share, particularly in the wake of global health crises such as COVID-19. The demand for prenatal and genetic testing is increasing, reflecting growing awareness and advancements in reproductive health technologies.

The 'End User' segment sees hospitals and diagnostic laboratories as primary consumers, given their role in providing comprehensive healthcare services. The rise of home healthcare and telemedicine is expanding the market for at-home diagnostic kits, driven by the convenience and accessibility they offer. Research institutes are also significant contributors, as they continue to explore innovative diagnostic solutions and technologies.

In the 'Component' segment, reagents and kits dominate due to their essential role in conducting diagnostic tests. The demand for advanced reagents is increasing as they enhance test accuracy and reliability. Instruments and software are also crucial, with ongoing innovations aimed at improving automation and data analysis capabilities. The integration of cloud-based solutions is a notable trend, facilitating real-time data sharing and collaboration across healthcare networks.

Geographical Overview

North America: The Next-Gen Diagnostic Tests Market in North America is mature, driven by advanced healthcare infrastructure and significant R&D investments. The United States leads the region, with strong demand from the biotechnology and pharmaceutical industries. Canada also contributes notably, focusing on personalized medicine and early disease detection.

Europe: Europe exhibits moderate market maturity, with robust demand from the healthcare and life sciences sectors. Key countries include Germany, the UK, and France, where government initiatives support innovation in diagnostic technologies, emphasizing precision medicine and early intervention.

Asia-Pacific: The Asia-Pacific region is experiencing rapid growth, driven by increasing healthcare expenditure and technological advancements. China and India are notable contributors, with expanding healthcare infrastructure and a growing focus on early diagnosis and preventive care. Japan also plays a significant role, leveraging its technological expertise.

Latin America: The market in Latin America is emerging, with Brazil and Mexico leading the demand for diagnostic tests. The region's growth is fueled by improving healthcare access and rising awareness of advanced diagnostic solutions, although challenges remain in terms of infrastructure and regulatory frameworks.

Middle East & Africa: The Middle East & Africa region is in the nascent stages of market development. The UAE and South Africa are notable countries, with investments in healthcare infrastructure and a growing emphasis on early disease detection. However, the region faces challenges related to economic disparities and limited access to advanced technologies.

Key Trends and Drivers

Trend 1 Title: Technological Advancements in Genomic Sequencing

The next-gen diagnostic tests market is significantly influenced by rapid advancements in genomic sequencing technologies. These advancements have led to more precise, faster, and cost-effective diagnostic solutions, enabling early detection and personalized treatment plans. The integration of AI and machine learning with genomic data analysis is further enhancing the accuracy of diagnostics, making it a critical component in precision medicine. This trend is driving increased adoption across healthcare providers seeking to improve patient outcomes.

Trend 2 Title: Regulatory Support and Frameworks

The establishment of supportive regulatory frameworks by health authorities globally is a key driver for the next-gen diagnostic tests market. Regulatory bodies are increasingly recognizing the importance of innovative diagnostic solutions in improving healthcare delivery. Streamlined approval processes and clear guidelines are encouraging companies to invest in R&D and bring new diagnostic technologies to market more swiftly. This regulatory support is crucial in fostering innovation and ensuring the availability of reliable diagnostic tests.

Trend 3 Title: Rise of Point-of-Care Testing

The demand for point-of-care (POC) testing is on the rise, driven by the need for rapid and accurate diagnostic results. Next-gen diagnostic tests are increasingly being designed for use at the point of care, offering convenience and efficiency in patient management. This trend is particularly prominent in remote and underserved areas where access to traditional laboratory facilities is limited. The ability to perform tests at the point of care is transforming healthcare delivery by enabling timely decision-making and reducing the burden on centralized laboratories.

Trend 4 Title: Integration of Digital Health Technologies

The integration of digital health technologies with next-gen diagnostic tests is revolutionizing the market. Wearable devices, mobile health applications, and telemedicine platforms are being used to collect and analyze health data in real-time. This integration allows for continuous monitoring and personalized healthcare solutions, enhancing patient engagement and adherence to treatment plans. The convergence of digital health and diagnostics is creating new opportunities for innovation and improving the overall efficiency of healthcare systems.

Trend 5 Title: Increasing Focus on Infectious Disease Diagnostics

The recent global health crises have underscored the importance of robust diagnostic capabilities for infectious diseases. There is a growing focus on developing next-gen diagnostic tests that can rapidly identify pathogens and provide actionable insights for disease management. This trend is driving investments in research and development to create tests that are not only fast and accurate but also scalable and adaptable to emerging infectious threats. The emphasis on infectious disease diagnostics is expected to continue as part of global efforts to strengthen healthcare resilience and preparedness.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Mode
  • 2.9 Key Market Highlights by Stage
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Molecular Diagnostics
    • 4.1.2 Immunoassays
    • 4.1.3 Point-of-Care Testing
    • 4.1.4 Companion Diagnostics
    • 4.1.5 Liquid Biopsy
    • 4.1.6 Microbiome Testing
    • 4.1.7 Genetic Testing
    • 4.1.8 Proteomics
    • 4.1.9 Metabolomics
    • 4.1.10 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Instruments
    • 4.2.2 Reagents & Kits
    • 4.2.3 Software
    • 4.2.4 Consumables
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting Services
    • 4.3.2 Maintenance Services
    • 4.3.3 Training Services
    • 4.3.4 Data Management Services
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 Mass Spectrometry
    • 4.4.4 Microarray
    • 4.4.5 Flow Cytometry
    • 4.4.6 CRISPR
    • 4.4.7 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Infectious Diseases
    • 4.5.3 Cardiology
    • 4.5.4 Neurology
    • 4.5.5 Prenatal Testing
    • 4.5.6 Rare Diseases
    • 4.5.7 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Academic & Research Institutes
    • 4.6.4 Pharmaceutical & Biotechnology Companies
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Hardware
    • 4.7.2 Software
    • 4.7.3 Services
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 Automated
    • 4.8.2 Semi-Automated
    • 4.8.3 Manual
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Research
    • 4.9.2 Development
    • 4.9.3 Commercialization
    • 4.9.4 Others
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Integrated Solutions
    • 4.10.2 Standalone Solutions
    • 4.10.3 Custom Solutions
    • 4.10.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Mode
      • 5.2.1.9 Stage
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Mode
      • 5.2.2.9 Stage
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Mode
      • 5.2.3.9 Stage
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Mode
      • 5.3.1.9 Stage
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Mode
      • 5.3.2.9 Stage
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Mode
      • 5.3.3.9 Stage
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Mode
      • 5.4.1.9 Stage
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Mode
      • 5.4.2.9 Stage
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Mode
      • 5.4.3.9 Stage
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Mode
      • 5.4.4.9 Stage
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Mode
      • 5.4.5.9 Stage
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Mode
      • 5.4.6.9 Stage
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Mode
      • 5.4.7.9 Stage
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Mode
      • 5.5.1.9 Stage
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Mode
      • 5.5.2.9 Stage
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Mode
      • 5.5.3.9 Stage
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Mode
      • 5.5.4.9 Stage
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Mode
      • 5.5.5.9 Stage
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Mode
      • 5.5.6.9 Stage
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Mode
      • 5.6.1.9 Stage
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Mode
      • 5.6.2.9 Stage
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Mode
      • 5.6.3.9 Stage
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Mode
      • 5.6.4.9 Stage
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Mode
      • 5.6.5.9 Stage
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Roche Diagnostics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Abbott Laboratories
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Thermo Fisher Scientific
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Siemens Healthineers
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Danaher Corporation
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Becton Dickinson and Company
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Bio-Rad Laboratories
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Hologic
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Qiagen
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Illumina
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Agilent Technologies
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 PerkinElmer
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 bioMerieux
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Sysmex Corporation
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Genomic Health
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Luminex Corporation
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Myriad Genetics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Exact Sciences
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Cepheid
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Adaptive Biotechnologies
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us